| Literature DB >> 29486303 |
Sharon S Y Leung1, Thaigarajan Parumasivam2, An Nguyen1, Thomas Gengenbach3, Elizabeth A Carter4, Nicholas B Carrigy5, Hui Wang5, Reinhard Vehring5, Warren H Finlay5, Sandra Morales6, Warwick J Britton7, Elizabeth Kutter8, Hak-Kim Chan9.
Abstract
This study aimed to assess the robustness of using a spray drying approach and formulation design in producing inhalable phage powders. Two types of Pseudomonas phages, PEV2 (Podovirus) and PEV40 (Myovirus) in two formulations containing different amounts of trehalose (70% and 60%) and leucine (30% and 40%) were studied. Most of the surface of the produced powders was found to be covered in crystalline leucine. The powders were stored at 4 °C and 20 °C under vacuum. The phage stability and in vitro aerosol performance of the phage powders were examined on the day of production and after 1, 3 and 12 months of storage. A minor titer loss during production was observed for both phages (0.2-0.8 log10 pfu/ml). The storage stability of the produced phage powders was found to be phage and formulation dependent. No further reduction in titer occurred for PEV2 powders stored at 4 °C across the study. The formulation containing 30% leucine maintained the viability of PEV2 at 20 °C, while the formulation containing 40% leucine gradually lost titer over time with a storage reduction of ∼0.9 log10 pfu/ml measured after 12 months. In comparison, the PEV40 phage powders generally had a ∼ 0.5 log10 pfu/ml loss upon storage regardless of temperature. When aerosolized, the total in vitro lung doses of PEV2 were of the order of 107 pfu, except the formulation containing 40% leucine stored at 20 °C which had a lower lung dose. The PEV40 powders also had lung doses of 106-107 pfu. The results demonstrate that spray dried Myoviridae and Podoviridae phage in a simple formulation of leucine and trehalose can be successfully stored for one year at 4 °C and 20 °C with vacuum packaging.Entities:
Keywords: Antibiotic resistance; PEV2; PEV40; Phage; Phage dry powder; Pulmonary infections
Mesh:
Substances:
Year: 2018 PMID: 29486303 PMCID: PMC5948144 DOI: 10.1016/j.ejpb.2018.02.033
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571